Elron Electronic Industries : Financial Statements as of September 30, 2021
November 15, 2021
Share
ELRON ELECTRONIC INDUSTRIES LTD.
English Translation of Periodic Report for the Third Quarter of 2021
Filed with the Israel Securities Authority
Part
Content
I
Material Changes and Updates that Occurred in Elron's Business
II
Board of Directors Report
III
Interim Financial Statements
IV
Effectiveness of the Internal Control over Financial Reporting and
Disclosure
ELRON ELECTRONIC INDUSTRIES LTD.
English Translation of Periodic Report for the Third Quarter of 2021
Filed with the Israel Securities Authority
Part I
Material Changes and Updates that Occurred in Elron's Business for the Three Months ended September 30, 2021
Elron Electronic Industries Ltd.
("Elron" or the "Company")
English Translation of Quarterly Report
for the Third Quarter of 2021
Part I
Material Changes and Updates that Occurred in the Company's
Business in the Three Months Ended September 30, 2021
Details according to Regulation 39A of the Israel Securities Regulations (Periodic
and Immediate Reports), 1970
In this section:
"Board of Directors Report"
English Translation of Elron's Board of
Directors Report for the Third Quarter of
2021, included in Part II of this report.
"Financial Statements"
English Translation of Elron's Interim
Consolidated Financial Statements as of
September 30, 2021, included in Part III of
this report.
"Annual Report"
Elron's Annual Report for the year ended
December 31, 2020 filed with the Israeli
Securities Authority.
The rest of the terms in this report shall have the meaning ascribed to them in the Annual Report, unless stated explicitly otherwise.
The matters described below are in addition to the developments and changes that occurred in the first three quarters of 2021 that were already previously described in Part I of the Company's Quarterly Report for the First or Second Quarter of 2021. The matters described below are presented according to the section numbers in Part I of the Annual Report.
1
1. Section 15 of Part I of the Annual Report - Investments
In the first nine months of 2021, Elron (directly and indirectly) invested approximately $13.5 million in the group companies. For further details, see Section 1.4 of the Board of Directors Report and Note 3 to the Financial Statements.
2. Section 24 of Part I of the Annual Report - BrainsGate
Section 24.11- In regard with BrainsGate's application for PMA marketing approval submitted to the FDA, in August 2021 BrainsGate has updated that the FDA has informed BrainsGate that it will bring BrainsGate's marketing approval application to a panel meeting which is expected to take place by the end of the year.
3. Section 25 of Part I of the Annual Report - CartiHeal
Sections 25.11- Further to the Annual Report, regarding CartiHeal's submission of the Agili-C implant's modular PMA to the FDA, in September 2021, CartiHeal completed the submission to the FDA of the clinical and final module of the PMA application and therefore completed the FDA PMA application.
Sections 25.13- Further to the Annual Report, regarding the transaction for the investment in and option for the sale of CartiHeal, in August 2021, Bioventus (the "Purchaser") announced that it decided to proceed with the investment and option transaction for the sale of CartiHeal to the Purchaser (the "Transaction"), and subsequently deposited an escrow payment of $50 million to ensure the exercise of the call option and put option.
The Purchaser further announced that the above decision came following its review of a statistical analysis report of the pivotal clinical trial of the Agili-C implant, reimbursement coding analysis and significant market diligence including surgeon interviews with respect to Agili-C's commercialization opportunity and ultimate market potential.
2
Yaron Elad
Niv Levy
CEO
CFO
November 14, 2021, Tel Aviv, Israel
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Elron Electronic Industries Ltd. published this content on 15 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2021 19:32:01 UTC.
Elron Electronic Industries Ltd. is an operational holding company that focuses on building and enhancing technology companies, mainly in the field of medical devices. Its group companies include companies at different stages of development and business maturation, operating in various technology fields, such as medical device and other fields. It is involved in the management of its group companies by means of membership and providing assistance to management. It operates in the Holdings and Corporate Operations segment. It is engaged in matters of policy guidance, strategic planning, marketing, selecting and manning senior management positions, determining the business plan, approving investments and budgets, development and operational guidance, assistance in creating strategic partnerships, and the overall ongoing monitoring of its group companies' performance. Its main group companies include BrainsGate Ltd, Pocared Diagnostics Ltd. and RDC Rafael Development Corporation Ltd.